Sertraline in children and adolescents with major depressive disorder

Craig L. Donnelly, Karen Wagner, Moira Rynn, Paul Ambrosini, Phyllis Landau, Ruoyong Yang, Christopher J. Wohlberg

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and Clinical Global Impressions-Improvement predefined criteria. RESULTS: There were no statistically significant differences in time to first response or first persistent response between sertraline and placebo in children, except for time to first response on Clinical Global Impressions-Improvement. Sertraline had a significantly faster time to first persistent response in adolescents compared to placebo. Within treatment groups, children had a significantly faster time to first response than adolescents, whether treated with placebo or sertraline, but not on time to first persistent response. Both age groups showed similar improvement over 34 weeks of treatment. CONCLUSION: In the double-blind studies, children and adolescents had different patterns of response with sertraline vs. placebo.

Original languageEnglish (US)
Pages (from-to)1162-1170
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Sertraline
Major Depressive Disorder
Placebos
Double-Blind Method
Age Groups
antineoplaston A10
Therapeutics
Reaction Time
Depression

Keywords

  • Major depressive disorder
  • Sertraline
  • Time to response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Sertraline in children and adolescents with major depressive disorder. / Donnelly, Craig L.; Wagner, Karen; Rynn, Moira; Ambrosini, Paul; Landau, Phyllis; Yang, Ruoyong; Wohlberg, Christopher J.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 10, 10.2006, p. 1162-1170.

Research output: Contribution to journalArticle

Donnelly, Craig L. ; Wagner, Karen ; Rynn, Moira ; Ambrosini, Paul ; Landau, Phyllis ; Yang, Ruoyong ; Wohlberg, Christopher J. / Sertraline in children and adolescents with major depressive disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2006 ; Vol. 45, No. 10. pp. 1162-1170.
@article{f924219a969742ceb70665e193078143,
title = "Sertraline in children and adolescents with major depressive disorder",
abstract = "OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and Clinical Global Impressions-Improvement predefined criteria. RESULTS: There were no statistically significant differences in time to first response or first persistent response between sertraline and placebo in children, except for time to first response on Clinical Global Impressions-Improvement. Sertraline had a significantly faster time to first persistent response in adolescents compared to placebo. Within treatment groups, children had a significantly faster time to first response than adolescents, whether treated with placebo or sertraline, but not on time to first persistent response. Both age groups showed similar improvement over 34 weeks of treatment. CONCLUSION: In the double-blind studies, children and adolescents had different patterns of response with sertraline vs. placebo.",
keywords = "Major depressive disorder, Sertraline, Time to response",
author = "Donnelly, {Craig L.} and Karen Wagner and Moira Rynn and Paul Ambrosini and Phyllis Landau and Ruoyong Yang and Wohlberg, {Christopher J.}",
year = "2006",
month = "10",
doi = "10.1097/01.chi.0000233204.51050.f0",
language = "English (US)",
volume = "45",
pages = "1162--1170",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Sertraline in children and adolescents with major depressive disorder

AU - Donnelly, Craig L.

AU - Wagner, Karen

AU - Rynn, Moira

AU - Ambrosini, Paul

AU - Landau, Phyllis

AU - Yang, Ruoyong

AU - Wohlberg, Christopher J.

PY - 2006/10

Y1 - 2006/10

N2 - OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and Clinical Global Impressions-Improvement predefined criteria. RESULTS: There were no statistically significant differences in time to first response or first persistent response between sertraline and placebo in children, except for time to first response on Clinical Global Impressions-Improvement. Sertraline had a significantly faster time to first persistent response in adolescents compared to placebo. Within treatment groups, children had a significantly faster time to first response than adolescents, whether treated with placebo or sertraline, but not on time to first persistent response. Both age groups showed similar improvement over 34 weeks of treatment. CONCLUSION: In the double-blind studies, children and adolescents had different patterns of response with sertraline vs. placebo.

AB - OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and Clinical Global Impressions-Improvement predefined criteria. RESULTS: There were no statistically significant differences in time to first response or first persistent response between sertraline and placebo in children, except for time to first response on Clinical Global Impressions-Improvement. Sertraline had a significantly faster time to first persistent response in adolescents compared to placebo. Within treatment groups, children had a significantly faster time to first response than adolescents, whether treated with placebo or sertraline, but not on time to first persistent response. Both age groups showed similar improvement over 34 weeks of treatment. CONCLUSION: In the double-blind studies, children and adolescents had different patterns of response with sertraline vs. placebo.

KW - Major depressive disorder

KW - Sertraline

KW - Time to response

UR - http://www.scopus.com/inward/record.url?scp=33749048134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749048134&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000233204.51050.f0

DO - 10.1097/01.chi.0000233204.51050.f0

M3 - Article

VL - 45

SP - 1162

EP - 1170

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 10

ER -